(SDAX, Financial Services)



-		Value Indicators:	EUR	Share data:		Description:	
Buy EUR 178.50		DCF:	178.38	Bloomberg: Reuters: ISIN:	HYQ GR HYQGn.DE DE0005493365	Technology-based financial provider	services
		Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2018e
		Market cap:	984.90	Freefloat	59.6 %	Beta:	1.3
		No. of shares (m):	6.24	Revenia (Ronald Slabke	e) 36.3 %	Price / Book:	6.6 x
Price	EUR 157.80	EV:	1,002.86	Treasury shares	4.1 %	Equity Ratio:	64 %
Upside	13.1 %	Freefloat MC:	587.00			Net Fin. Debt / EBITDA:	0.5 x
		Ø Trad. Vol. (30d):	1.27 m			Net Debt / EBITDA:	0.5 x

Convincing strategy with growth and margin potential

Mr. Slabke, CEO of Hypoport AG, attended several one-on-one meetings and gave a presentation at our Warburg Highlights conference.

Presentation Highlights


- Unchanged market conditions in the real estate sector continue to be favourable for Hypoport's business model. The fear of collapsing house prices with the bursting of a property bubble appears unfounded. Demand in the German housing market continues to far outstrip supply and in urban areas in particular, affordable housing is scarce. An increase in interest rates, which would also cause prices to drop, is unlikely, in our view, owing to the risk of a default of the Italian economy among other factors.
- Most investors were interested in the company's recent acquisitions. The integration of FIO Systems AG and the Value AG completes the range of services offered in connection with a real estate transaction. While Hypoport so far covered the financial end of the transaction, these companies add services on the real estate side. FIO operates an ERP system used by most savings banks (savings banks are the largest brokers of real estate in Germany) and Value AG offers property valuation services for banks. This is a mandatory part of the mortgage process for banks and it could be more effectively processed centrally. Ultimately, all services are part of a single transaction and the sharing of large volumes of data lead to processing synergies for Hypoport.
- Besides the mentioned effects of broadening the value chain, the FIO acquisition improves the contact to the savings banks sector. As most of the banks already use the FIO solution, Hypoport intends to upsell its EUROPACE/FINMAS solution by integrating both products to a single solution in the final stage. This will increase the pace of adding new savings banks to the platform. While the number of savings banks on the platform should be directly triggered by the acquisition, cooperative banks lack such a trigger. However, Hypoport should grow at high rates in this sector as well, based on the competitive pressure on these banks. As other banks become more digitized and effective, cooperative banks will experience some pressure in the market and are therefore forced to optimize their processes, which is most likely to occur via Hypoport's solutions.
- The insurance business was the subject of some discussion as well. While the start of the business was slightly beyond Hypoport's plans in terms of broker penetration, the company experienced better than expected development with InsurTech companies and online platforms. However, we believe that the company is on track to become the relevant player in the market and, besides, the potential is huge.

Conclusion

- Company is perfectly on track and maintains its excellent market positions within its segments.
- Looking at the potential in the real estate and insurance markets, Hypoport has the opportunity to grow at high rates for a rather long time.
- Due to the strong and defendable market position, we see no real competitor for Hypoport and reiterate our Buy rating.

$\begin{array}{c} \begin{array}{c} here \\ here$	170 -	M JA	FY End: 31.12. in EUR m	CAGR (17-20e)	2014	2015	2016	2017	2018e	2019e	2020e
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	N		Sales	16.6 %	112.33	138.98	156.64	194.86	231.40	268.84	308.98
143 140 140 53.9 % 54.9 % 56.0 % 56.1 % 57.4 % 57.9 % 58.2 % 140 140 140 12.70 25.08 28.24 30.12 39.11 46.83 56.2 % 150 11.3 % 18.0 % 15.5 % 16.9 % 17.4 % 18.2 % 110 0117 0118 0318 0518 7.94 19.26 23.16 23.32 29.62 36.08 43.2 % 110 0117 0118 0318 0518 7.94 19.26 23.16 23.32 29.62 36.08 43.2 % Margin 7.1 % 13.9 % 14.8 % 12.0 % 12.8 % 13.4 % 14.2 % Net income 22.6 % 5.92 15.87 18.07 18.42 23.02 27.93 33.9 % PS adj. 20.6 % 0.97 2.56 3.00 3.10 3.69 4.47 5.4 % Dividend Yield n.a. n.a		, vr vr	Change Sales yoy		14.5 %	23.7 %	12.7 %	24.4 %	18.8 %	16.2 %	14.9 %
Margin 11.3 % 18.0 % 15.5 % 16.9 % 17.4 % 18.2 % Margin 23.5 % 7.94 19.26 23.16 23.32 29.62 36.08 43.8 Margin 7.1 % 13.9 % 14.8 % 12.0 % 12.8 % 13.4 % 14.2 % Margin 7.1 % 13.9 % 14.8 % 12.0 % 12.8 % 13.4 % 14.2 % Margin 7.1 % 13.9 % 14.8 % 12.0 % 12.8 % 13.4 % 14.2 % Margin 7.1 % 13.9 % 14.8 % 12.0 % 12.8 % 13.4 % 14.2 % Margin 22.6 % 5.92 15.87 18.07 18.42 23.02 27.93 33.8 PS 20.6 % 0.97 2.56 3.00 3.10 3.69 4.47 5.4 Dividend Yield - - 0.00 <td></td> <td>J ' </td> <td>Gross profit margin</td> <td></td> <td>53.9 %</td> <td>54.9 %</td> <td>58.0 %</td> <td>56.1 %</td> <td>57.4 %</td> <td>57.9 %</td> <td>58.2 %</td>		J '	Gross profit margin		53.9 %	54.9 %	58.0 %	56.1 %	57.4 %	57.9 %	58.2 %
130 17.3 % 16.0 % 17.3 % 16.0 % 17.3 % 16.0 % 17.4 %		i Miri I	EBITDA	23.1 %	12.70	25.08	28.24	30.12	39.11	46.83	56.23
125 126 128 129 128 129 128 128 13.4 14.2 120 07/17 09/17 11/17 01/18 03/18 05/18 12.0 12.8 13.4 14.2 100 07/17 09/17 11/17 01/18 03/18 05/18 13.4 14.2 100 07/17 09/17 11/17 01/18 03/18 05/18 14.2 14.8% 12.0% 12.8% 13.4 14.2 PS 20.6% 0.97 2.56 3.00 3.10 3.69 4.47 5.4 EPS 20.6% 0.97 2.56 3.00 3.10 3.69 4.47 5.4 DPS - 0.00 <t< td=""><td></td><td>1 monthan</td><td>Margin</td><td></td><td>11.3 %</td><td>18.0 %</td><td>18.0 %</td><td>15.5 %</td><td>16.9 %</td><td>17.4 %</td><td>18.2 %</td></t<>		1 monthan	Margin		11.3 %	18.0 %	18.0 %	15.5 %	16.9 %	17.4 %	18.2 %
I15 Net income 22.6 % 5.92 15.87 18.07 18.42 23.02 27.93 33.9 07/7 09/7 11/17 01/18 03/18 05/18 - 0.00 0.07 2.56 3.00 3.10 3.69 4.47 5.4 Prypoport SDAX (normalised) DPS - 0.00		May 10 + +	EBIT	23.5 %	7.94	19.26	23.16	23.32	29.62	36.08	43.88
Import Net income 22.6 % 5.92 15.87 18.07 18.42 23.02 27.93 33.93 Import Oprit Intro Office Oprit Intro Import Sobax (normalsed) Import Import Sobax (normalsed) Import Import Sobax (normalsed) Import Import Sobax (normalsed) Import	120	· ·	Margin		7.1 %	13.9 %	14.8 %	12.0 %	12.8 %	13.4 %	14.2 %
OT/17 OM/17 OM/18 OM/17 OM/18 OM/17 Concentration Om/18 OM/18 OM/18 OM/18 OM/18 OM/18 OM/18 OM/17 Concentration Om/18 OM/18<	115		Net income	22.6 %	5.92	15.87	18.07	18.42	23.02	27.93	33.98
DPS 0.00		3/18 05/18	EPS	20.6 %	0.97	2.56	3.00	3.10	3.69	4.47	5.44
DPS - 0.00 <th< td=""><td></td><td></td><td>EPS adj.</td><td>20.6 %</td><td>0.97</td><td>2.56</td><td>3.00</td><td>3.10</td><td>3.69</td><td>4.47</td><td>5.44</td></th<>			EPS adj.	20.6 %	0.97	2.56	3.00	3.10	3.69	4.47	5.44
1 month: 5.9 % 6 months: 4.7 % Year to date: 6.5 % Trailing 12 months: 23.7 % EV / Sales 0.6 x 1.4 x 2.8 x 3.5 x 4.4 x 3.8 x 3.2 c Company events: 0.6 x 1.4 x 2.8 x 3.5 x 4.4 x 3.8 x 3.2 c 06.08.18 Q2 P/E 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 x 05.11.18 Q3 Net Debt 4.08 -13.29 -11.46 2.15 17.96 9.68 4.9 c		mansed)	DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1 month: 5.9 % FCFPS 0.37 3.16 1.78 -0.48 2.27 3.25 4.2 6 months: 4.7 % FCF / Market cap 3.3 % 10.2 % 2.2 % -0.3 % 1.4 % 2.0 % 2.7 % Year to date: 6.5 % EV / Sales 0.6 x 1.4 x 2.8 x 3.5 x 4.4 x 3.8 x 3.2 x Trailing 12 months: 23.7 % EV / EBITDA 5.6 x 7.8 x 15.6 x 22.6 x 26.0 x 21.6 x 17.7 Company events: 0.6.08.18 0.2 % 10.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 x 05.11.18 023 Net Debt ROCE (NOPAT) 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.90 Net Debt 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.90	Rel. Performance vs SDA	X:	Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
6 months: 4.7 % 4.7 % EV / Sales 0.6 x 1.4 x 2.8 x 3.5 x 4.4 x 3.8 x 3.2 x Year to date: 6.5 % EV / EBITDA 5.6 x 7.8 x 15.6 x 22.6 x 26.0 x 21.6 x 3.3 x 3.2 x Trailing 12 months: 23.7 % EV / EBITDA 5.6 x 7.8 x 15.6 x 22.6 x 26.0 x 21.6 x 17.7 % Company events: 0.3 7 % 10.2 x 19.0 x 20.5 x 36.8 x 42.8 x 35.3 x 29.0 x 06.08.18 022 05.11.18 03 FCF Potential Yield 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 x 05.11.18 03 Met Debt 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.92 Net Debt 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.92 ROCE (NOPAT) 15.8 % 38.9 % 39.7 % 27.1 % 18.3 % 15.8 % 17.3 %			FCFPS		0.37	3.16	1.78	-0.48	2.27	3.25	4.27
Year to date: 6.5 % 0.6 x 1.4 x 2.8 x 3.5 x 4.4 x 3.8 x 3.2 x Trailing 12 months: 23.7 % EV / EBITDA 5.6 x 7.8 x 15.6 x 22.6 x 26.0 x 21.6 x 17.7 million Company events: 0.6.08.18 Q2 P / E adj. 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 x 05.11.18 Q3 Net Debt ROCE (NOPAT) 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.92			FCF / Market cap		3.3 %	10.2 %	2.2 %	-0.3 %	1.4 %	2.0 %	2.7 %
Trailing 12 months: 23.7 % EV / EBIT 9.0 x 10.2 x 19.0 x 29.1 x 34.4 x 28.0 x 22.7 Company events: P / E 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 06.08.18 Q2 FCF Potential Yield 15.9 % 11.2 % 5.3 % 3.8 % 3.2 % 3.9 % 4.7 % Net Debt ROCE (NOPAT) 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.95	6 months:		EV / Sales		0.6 x	1.4 x	2.8 x	3.5 x	4.4 x	3.8 x	3.2 x
Company events: P / E 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 06.08.18 Q2 D5.11.18 Q3 P / E adj. 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 05.11.18 Q3 Net Debt 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.95 ROCE (NOPAT) 15.8 % 38.9 % 39.7 % 27.1 % 18.3 % 15.8 % 17.3 %	Year to date:	6.5 %	EV / EBITDA		5.6 x	7.8 x	15.6 x	22.6 x	26.0 x	21.6 x	17.7 x
Company events: P / E 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 06.08.18 Q2 P / E adj. 11.3 x 13.2 x 25.0 x 36.8 x 42.8 x 35.3 x 29.0 05.11.18 Q3 FCF Potential Yield 15.9 % 11.2 % 5.3 % 3.8 % 3.2 % 3.9 % 4.7 % 05.11.18 Q3 Net Debt 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.9 NocE (NOPAT) 15.8 % 38.9 % 39.7 % 27.1 % 18.3 % 15.8 % 17.3 %	Trailing 12 months:	23.7 %	EV / EBIT		9.0 x	10.2 x	19.0 x	29.1 x	34.4 x	28.0 x	22.7 x
06.08.18 Q2 FCF Potential Yield 15.9 % 11.2 % 5.3 % 3.8 % 3.2 % 3.9 % 4.7 % 05.11.18 Q3 Net Debt ROCE (NOPAT) 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.9 15.8 % 38.9 % 39.7 % 27.1 % 18.3 % 15.8 % 17.3 %	3		P/E		11.3 x	13.2 x	25.0 x	36.8 x	42.8 x	35.3 x	29.0 x
Net Debt 4.08 -13.29 -11.46 2.15 17.96 9.68 -4.9 ROCE (NOPAT) 15.8 % 38.9 % 39.7 % 27.1 % 18.3 % 15.8 % 17.3 %	Company events:		P / E adj.		11.3 x	13.2 x	25.0 x	36.8 x	42.8 x	35.3 x	29.0 x
ROCE (NOPAT) 15.8 % 38.9 % 39.7 % 27.1 % 18.3 % 15.8 % 17.3 %	06.08.18	Q2	FCF Potential Yield		15.9 %	11.2 %	5.3 %	3.8 %	3.2 %	3.9 %	4.7 %
	05.11.18	Q3	Net Debt		4.08	-13.29	-11.46	2.15	17.96	9.68	-4.95
Guidance: 2018: Revenue between EUR 220m and 240m and EBIT between EUR 26m and 31m			ROCE (NOPAT)		15.8 %	38.9 %	39.7 %	27.1 %	18.3 %	15.8 %	17.3 %
			Guidance:	2018: Revenu	e between E	UR 220m an	d 240m and I	EBIT betwee	n EUR 26m a	and 31m	






Company Background

- The company, founded in 1999, is specialised as a property financing intermediary and is targeting the insurance market as next field of growth
- With EUROPACE, Hypoport operates the largest German online B2B platform for property financing and similar products
- Under the Dr. Klein brand, Hypoport operates a franchise system of stationary advisors for private customers
- Hypoport is also in a leading position in the area of institutional property financing (also under the Dr. Klein brand)
- An advanced level of technology is shown in all segments (fintech)

Competitive Quality

- The online B2B marketplace for property financing (EUROPACE) is the largest of its kind in Germany
- As the number of affiliated suppliers is decisive for marketplaces of this type, this forms a central competitive advantage and a considerable market entry barrier for third parties.
- The Dr. Klein business segments (private clients) benefits from market access over EUROPACE but also from the many years of experience in the area of property financing
- Dr. Klein has regional presence (approx. 200 branches) and, in this way, achieves customer proximity.
- Most importantly however Dr. Klein is strongly focused (mainly property financing) and neutral (with offers from every provider). Other financial sales teams or retail banks normally cannot afford both.





DCF model														
	Detaile	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	
Sales	231.40	268.84	308.98	353.78	403.31	455.74	508.15	558.97	600.89	630.94	656.17	675.86	696.13	
Sales change	18.8 %	16.2 %	14.9 %	14.5 %	14.0 %	13.0 %	11.5 %	10.0 %	7.5 %	5.0 %	4.0 %	3.0 %	3.0 %	3.0 %
EBIT	29.62	36.08	43.88	53.07	64.53	77.48	91.47	103.41	114.17	119.88	124.67	128.41	132.27	
EBIT-margin	12.8 %	13.4 %	14.2 %	15.0 %	16.0 %	17.0 %	18.0 %	18.5 %	19.0 %	19.0 %	19.0 %	19.0 %	19.0 %	
Tax rate (EBT)	21.8 %	21.9 %	21.9 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	22.0 %	
NOPAT	23.18	28.16	34.29	41.39	50.33	60.43	71.34	80.66	89.05	93.50	97.24	100.16	103.17	
Depreciation	9.49	10.75	12.36	14.15	16.13	18.23	20.33	22.36	24.04	25.24	26.25	27.03	27.85	
in % of Sales	4.1 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	
Changes in provisions	0.00	0.00	0.00	0.17	0.05	0.05	0.05	0.05	0.04	0.03	0.03	0.02	0.02	
Change in Liquidity from														
- Working Capital	6.82	5.40	5.70	5.53	6.93	7.34	7.34	7.11	5.87	4.21	3.53	2.76	2.84	
- Capex	11.50	13.00	14.00	15.92	18.15	20.51	22.87	25.15	27.04	25.24	26.25	27.03	27.85	
Capex in % of Sales	5.0 %	4.8 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.0 %	4.0 %	4.0 %	4.0 %	
Other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Free Cash Flow (WACC Model)	14.34	20.52	26.95	34.27	41.43	50.86	61.52	70.80	80.22	89.33	93.74	97.43	100.35	103
PV of FCF	13.60	17.96	21.77	25.56	28.53	32.34	36.10	38.36	40.12	41.25	39.96	38.34	36.45	705
share of PVs		4.78 %						32.00) %					63.22 %
Model parameter							Valuat	ion (m)						
Derivation of WACC:			Derivation	of Beta:				t values 20	030e	41				
Debt ratio	5.00 %		Financial S	Strongth		1.00		al Value	c	70	6			
Cost of debt (after tax)	2.1 %		Liquidity (s	0		1.00		n liabilities	-		0			
Market return	7.00 %		Cyclicality			1.60	Hybrid				0			
Risk free rate	1.50 %		Transparer	ncv		1.40		v interest			0			
	1.50 /0		Others	,		1.30		val. of inv	estments		0			
							Liquidit	у		1	4	No. of sha	ares (m)	6.2
WACC	8.32 %		Beta			1.30	Equity	Value		1,11	3	Value per	share (E	UR) 178.38

Sensitivity Value per Share (EUR)

		Terminal (Growth								Delta EBIT	-margin					
Beta V	NACC	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	3.50 %	3.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.49 9	9.3 %	136.65	139.43	142.41	145.63	149.12	152.91	157.03	1.49	9.3 %	132.54	136.91	141.27	145.63	150.00	154.36	158.72
1.40 8	3.8 %	149.44	152.85	156.55	160.56	164.93	169.71	174.97	1.40	8.8 %	146.24	151.01	155.79	160.56	165.33	170.11	174.88
1.35 8	3.6 %	156.62	160.42	164.56	169.06	173.98	179.39	185.36	1.35	8.6 %	154.04	159.04	164.05	169.06	174.06	179.07	184.08
1.30 8	3.3 %	164.42	168.67	173.31	178.38	183.95	190.10	196.92	1.30	8.3 %	162.59	167.85	173.11	178.38	183.64	188.90	194.16
1.25 8	3.1 %	172.91	177.68	182.90	188.64	194.97	201.99	209.83	1.25	8.1 %	172.01	177.55	183.09	188.64	194.18	199.73	205.27
1.20 7	7.8 %	182.19	187.56	193.47	199.99	207.22	215.29	224.35	1.20	7.8 %	182.43	188.28	194.13	199.99	205.84	211.70	217.55
1.11 7	7.3 %	203.58	210.49	218.16	226.72	236.33	247.19	259.58	1.11	7.3 %	206.96	213.55	220.13	226.72	233.30	239.89	246.47

• The growth anticipated for Hypoport is based on robust business development in all segments

• Financial Services (Europace) in particular offers systematic potential for economies of scale and margin growth

• On this basis we assume a positive long-term margin trend

• Based on a sophisticated regional dispersion of tax obligations a low tax rate is assumed long term.



Valuation							
	2014	2015	2016	2017	2018e	2019e	2020e
Price / Book	1.7 x	4.0 x	7.0 x	8.2 x	6.6 x	5.6 x	4.7 x
Book value per share ex intangibles	1.25	3.40	3.72	4.41	2.73	4.78	7.81
EV / Sales	0.6 x	1.4 x	2.8 x	3.5 x	4.4 x	3.8 x	3.2 x
EV / EBITDA	5.6 x	7.8 x	15.6 x	22.6 x	26.0 x	21.6 x	17.7 x
EV / EBIT	9.0 x	10.2 x	19.0 x	29.1 x	34.4 x	28.0 x	22.7 x
EV / EBIT adj.*	9.0 x	10.2 x	19.0 x	29.1 x	34.4 x	28.0 x	22.7 x
P / FCF	29.9 x	9.8 x	45.6 x	n.a.	69.5 x	48.6 x	37.0 x
P/E	11.3 x	13.2 x	25.0 x	36.8 x	42.8 x	35.3 x	29.0 x
P / E adj.*	11.3 x	13.2 x	25.0 x	36.8 x	42.8 x	35.3 x	29.0 x
Dividend Yield	n.a.						
FCF Potential Yield (on market EV)	15.9 %	11.2 %	5.3 %	3.8 %	3.2 %	3.9 %	4.7 %
*Adjustments made for: -							

Consolidated profit & loss




In EUR m	2014	2015	2016	2017	2018e	2019e	2020e
Sales	112.33	138.98	156.64	194.86	231.40	268.84	308.98
Change Sales yoy	14.5 %	23.7 %	12.7 %	24.4 %	18.8 %	16.2 %	14.9 %
Increase / decrease in inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Own work capitalised	4.18	4.66	5.66	6.99	8.33	9.68	11.12
Total Sales	116.50	143.65	162.30	201.84	239.73	278.52	320.10
Material expenses	55.95	67.31	71.44	92.57	106.91	122.86	140.28
Gross profit	60.55	76.34	90.86	109.27	132.82	155.66	179.83
Gross profit margin	53.9 %	54.9 %	58.0 %	56.1 %	57.4 %	57.9 %	58.2 %
Personnel expenses	35.33	38.22	46.36	58.56	69.42	80.65	91.46
Other operating income	1.83	2.18	3.07	4.52	4.63	5.38	6.18
Other operating expenses	14.50	15.25	19.33	25.35	28.92	33.55	38.31
Unfrequent items	0.15	0.03	0.00	0.26	0.00	0.00	0.00
EBITDA	12.70	25.08	28.24	30.12	39.11	46.83	56.23
Margin	11.3 %	18.0 %	18.0 %	15.5 %	16.9 %	17.4 %	18.2 %
Depreciation of fixed assets	0.97	1.12	1.24	1.69	2.31	2.69	3.09
EBITA	11.73	23.96	27.00	28.44	36.79	44.14	53.14
Amortisation of intangible assets	3.80	4.70	3.84	5.12	7.17	8.07	9.27
Goodwill amortisation	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT	7.94	19.26	23.16	23.32	29.62	36.08	43.88
Margin	7.1 %	13.9 %	14.8 %	12.0 %	12.8 %	13.4 %	14.2 %
EBIT adj.	7.94	19.26	23.16	23.32	29.62	36.08	43.88
Interest income	0.14	0.37	0.23	0.55	0.80	0.80	0.80
Interest expenses	0.82	0.52	0.63	0.88	1.10	1.30	1.40
Other financial income (loss)	0.00	0.00	0.08	0.00	0.10	0.20	0.20
EBT	7.25	19.10	22.84	22.99	29.42	35.78	43.48
Margin	6.5 %	13.7 %	14.6 %	11.8 %	12.7 %	13.3 %	14.1 %
Total taxes	1.32	3.24	4.76	4.56	6.40	7.85	9.50
Net income from continuing operations	5.93	15.87	18.07	18.43	23.02	27.93	33.98
Income from discontinued operations (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income before minorities	5.93	15.87	18.07	18.43	23.02	27.93	33.98
Minority interest	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Net income	5.92	15.87	18.07	18.42	23.02	27.93	33.98
Margin	5.3 %	11.4 %	11.5 %	9.5 %	9.9 %	10.4 %	11.0 %
Number of shares, average	6.12	6.19	6.01	5.94	6.24	6.24	6.24
EPS	0.97	2.56	3.00	3.10	3.69	4.47	5.44
EPS adj.	0.97	2.56	3.00	3.10	3.69	4.47	5.44
*Adjustments made for:							

Guidance: 2018: Revenue between EUR 220m and 240m and EBIT between EUR 26m and 31m


Financial Ratios

2014	2015	2016	2017	2018e	2019e	2020e
92.5 %	85.3 %	85.6 %	88.3 %	86.7 %	86.2 %	85.4 %
7.0 x	6.0 x	1.6 x	0.0 x	1.4 x	1.3 x	1.4 x
15.4 x	48.0 x	45.0 x	34.3 x	35.6 x	36.0 x	40.2 x
18.2 %	16.9 %	20.8 %	19.9 %	21.8 %	21.9 %	21.9 %
0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	92.5 % 7.0 x 15.4 x 18.2 % 0.0 %	92.5 % 85.3 % 7.0 x 6.0 x 15.4 x 48.0 x 18.2 % 16.9 % 0.0 % 0.0 %	92.5 % 85.3 % 85.6 % 7.0 x 6.0 x 1.6 x 15.4 x 48.0 x 45.0 x 18.2 % 16.9 % 20.8 % 0.0 % 0.0 % 0.0 %	92.5 % 85.3 % 85.6 % 88.3 % 7.0 x 6.0 x 1.6 x 0.0 x 15.4 x 48.0 x 45.0 x 34.3 x 18.2 % 16.9 % 20.8 % 19.9 % 0.0 % 0.0 % 0.0 % 0.0 %	92.5 % 85.3 % 85.6 % 88.3 % 86.7 % 7.0 x 6.0 x 1.6 x 0.0 x 1.4 x 15.4 x 48.0 x 45.0 x 34.3 x 35.6 x 18.2 % 16.9 % 20.8 % 19.9 % 21.8 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %	92.5 % 85.3 % 85.6 % 88.3 % 86.7 % 86.2 % 7.0 x 6.0 x 1.6 x 0.0 x 1.4 x 1.3 x 15.4 x 48.0 x 45.0 x 34.3 x 35.6 x 36.0 x 18.2 % 16.9 % 20.8 % 19.9 % 21.8 % 21.9 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %

Sales, EBITDA in EUR m








- Gross profit margin - Total Operating Costs / Sales - EBIT margin

Performance per Share



COMMENT

5

Source: Warburg Research


Consolidated balance sheet



In EUR m	2014	2015	2016	2017	2018e	2019e	2020e
Assets							
Goodwill and other intangible assets	30.95	31.89	41.66	55.97	133.30	148.23	162.96
thereof other intangible assets	0.00	0.00	3.83	6.77	84.10	99.03	113.76
thereof Goodwill	0.00	0.00	0.00	24.77	24.77	24.77	24.77
Property, plant and equipment	2.66	3.04	2.63	4.45	4.13	3.44	2.35
Financial assets	0.08	0.03	1.09	1.43	1.43	1.43	1.43
Other long-term assets	1.12	1.42	3.01	4.09	4.09	4.09	4.09
Fixed assets	34.82	36.38	48.39	65.93	142.95	157.19	170.83
Inventories	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts receivable	29.62	32.85	38.09	49.14	58.30	67.80	77.90
Liquid assets	12.02	24.76	22.41	14.33	23.27	35.15	53.39
Other short-term assets	3.94	2.09	3.21	11.57	11.57	11.57	11.57
Current assets	45.59	59.70	63.71	75.05	93.15	114.53	142.86
Total Assets	80.40	96.10	112.10	141.00	236.10	271.70	313.70
Liabilities and shareholders' equity							
Subscribed capital	6.20	6.20	6.20	6.20	6.49	6.49	6.49
Capital reserve	2.21	2.35	2.35	2.91	47.67	47.67	47.67
Retained earnings	30.26	44.01	55.54	73.75	96.77	124.70	158.67
Other equity components	-0.08	-0.16	0.05	-0.25	-0.35	-0.35	-0.35
Shareholders' equity	38.59	52.39	64.13	82.60	150.58	178.51	212.48
Minority interest	0.26	0.27	0.27	0.31	0.31	0.31	0.31
Total equity	38.85	52.66	64.40	82.91	150.89	178.81	212.79
Provisions	0.20	0.21	0.25	0.18	0.18	0.18	0.18
thereof provisions for pensions and similar obligations	0.20	0.21	0.24	0.18	0.18	0.18	0.18
Financial liabilities (total)	15.90	11.26	10.71	16.30	41.05	44.65	48.25
thereof short-term financial liabilities	4.64	4.34	4.44	2.94	2.94	2.94	2.94
Accounts payable	16.49	20.39	18.71	23.06	25.40	29.50	33.90
Other liabilities	8.96	11.55	18.07	18.53	18.53	18.53	18.53
Liabilities	41.56	43.42	47.74	58.07	85.17	92.87	100.87
Total liabilities and shareholders' equity	80.40	96.10	112.10	141.00	236.10	271.70	313.70

Financial Ratios

	2014	2015	2016	2017	2018e	2019e	2020e
Efficiency of Capital Employment							
Operating Assets Turnover	7.1 x	9.0 x	7.1 x	6.4 x	6.2 x	6.4 x	6.7 x
Capital Employed Turnover	2.6 x	3.5 x	3.0 x	2.3 x	1.4 x	1.4 x	1.5 x
ROA	17.0 %	43.6 %	37.3 %	27.9 %	16.1 %	17.8 %	19.9 %
Return on Capital							
ROCE (NOPAT)	15.8 %	38.9 %	39.7 %	27.1 %	18.3 %	15.8 %	17.3 %
ROE	16.6 %	34.9 %	31.0 %	25.1 %	19.7 %	17.0 %	17.4 %
Adj. ROE	16.6 %	34.9 %	31.0 %	25.1 %	19.7 %	17.0 %	17.4 %
Balance sheet quality							
Net Debt	4.08	-13.29	-11.46	2.15	17.96	9.68	-4.95
Net Financial Debt	3.88	-13.50	-11.70	1.97	17.78	9.50	-5.14
Net Gearing	10.5 %	-25.2 %	-17.8 %	2.6 %	11.9 %	5.4 %	-2.3 %
Net Fin. Debt / EBITDA	30.5 %	n.a.	n.a.	6.5 %	45.5 %	20.3 %	n.a.
Book Value / Share	6.3	8.7	10.6	13.7	23.8	28.2	33.5
Book value per share ex intangibles	1.2	3.4	3.7	4.4	2.7	4.8	7.8



COMMENT

Published 26.06.2018

6

Consolidated cash flow statement




In EUR m	2014	2015	2016	2017	2018e	2019e	2020e
Net income	5.93	15.87	18.07	18.43	23.02	27.93	33.98
Depreciation of fixed assets	0.97	1.12	1.24	1.69	2.31	2.69	3.09
Amortisation of goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Amortisation of intangible assets	3.80	4.70	3.84	5.12	7.17	8.07	9.27
Increase/decrease in long-term provisions	0.00	0.00	0.03	0.00	0.00	0.00	0.00
Other non-cash income and expenses	0.03	1.60	0.00	-0.92	0.00	0.00	0.00
Cash Flow before NWC change	10.72	23.28	23.19	24.31	32.51	38.68	46.33
Increase / decrease in inventory	-4.13	-1.66	0.00	0.00	0.00	0.00	0.00
Increase / decrease in accounts receivable	0.00	0.00	-5.24	-11.05	-9.16	-9.50	-10.10
Increase / decrease in accounts payable	1.77	4.60	-1.69	4.35	2.34	4.10	4.40
Increase / decrease in other working capital positions	0.05	0.47	2.10	-9.36	0.00	0.00	0.00
Increase / decrease in working capital (total)	-2.31	3.41	-4.83	-16.06	-6.82	-5.40	-5.70
Net cash provided by operating activities [1]	8.42	26.69	18.36	8.26	25.69	33.28	40.63
Investments in intangible assets	-5.55	-4.70	-7.67	-8.00	-9.50	-11.00	-12.00
Investments in property, plant and equipment	-0.62	-0.62	-0.80	-2.00	-2.00	-2.00	-2.00
Payments for acquisitions	0.00	0.00	-5.56	-9.56	-75.00	-12.00	-12.00
Financial investments	0.02	0.01	0.03	0.55	0.00	0.00	0.00
Income from asset disposals	0.00	0.05	0.01	0.02	0.00	0.00	0.00
Net cash provided by investing activities [2]	-6.18	-7.06	-13.25	-21.19	-86.50	-25.00	-26.00
Change in financial liabilities	-0.85	-4.60	-0.50	4.85	24.75	3.60	3.60
Dividends paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of own shares	-0.31	-2.30	-6.91	0.00	0.00	0.00	0.00
Capital measures	0.00	0.00	0.00	0.00	45.00	0.00	0.00
Other	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net cash provided by financing activities [3]	-1.16	-6.90	-7.41	4.85	69.75	3.60	3.60
Change in liquid funds [1]+[2]+[3]	1.07	12.73	-2.29	-8.08	8.94	11.88	18.23
Effects of exchange-rate changes on cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash and cash equivalent at end of period	12.02	24.76	22.46	14.33	23.27	35.15	53.39

Financial Ratios


Financial Ratios							
	2014	2015	2016	2017	2018e	2019e	2020e
Cash Flow							
FCF	2.25	19.59	10.69	-2.84	14.19	20.28	26.63
Free Cash Flow / Sales	2.0 %	15.4 %	6.3 %	-0.9 %	6.1 %	7.5 %	8.6 %
Free Cash Flow Potential	11.38	21.84	23.48	25.56	32.71	38.98	46.73
Free Cash Flow / Net Profit	38.0 %	134.7 %	54.7 %	-9.5 %	61.6 %	72.6 %	78.4 %
Interest Received / Avg. Cash	1.2 %	2.0 %	1.0 %	3.0 %	4.3 %	2.7 %	1.8 %
Interest Paid / Avg. Debt	5.0 %	3.8 %	5.7 %	6.5 %	3.8 %	3.0 %	3.0 %
Management of Funds							
Investment ratio	5.5 %	3.8 %	5.4 %	5.1 %	5.0 %	4.8 %	4.5 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	129.5 %	91.4 %	166.6 %	146.9 %	121.2 %	120.9 %	113.3 %
Avg. Working Capital / Sales	10.0 %	9.2 %	10.2 %	11.7 %	12.7 %	13.2 %	13.3 %
Trade Debtors / Trade Creditors	179.6 %	161.1 %	203.6 %	213.1 %	229.5 %	229.8 %	229.8 %
Inventory Turnover	n.a.						
Receivables collection period (days)	96	86	89	92	92	92	92
Payables payment period (days)	108	111	96	91	87	88	88
Cash conversion cycle (Days)	n.a.						

CAPEX and Cash Flow in EUR m



Free Cash Flow Generation

Working Capital



COMMENT

Published 26.06.2018

7



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WHPG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.

3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.

4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in
 -2- the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.

MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.

- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6- Companies affiliated with Warburg Research regularly trade financial instruments of the analysed company or derivatives of these.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have other important interests in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
HYPOPORT	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005493365.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	110	54
Hold	89	44
Sell	4	2
Rating suspended	0	0
Total	203	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	33	72
Hold	13	28
Sell	0	0
Rating suspended	0	0
Total	46	100

PRICE AND RATING HISTORY HYPOPORT AS OF 26.06.2018



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

WARBURG

EQUITIES

Roland Rapelius Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Lucas Boventer Renewables, Internet, Media **Christian Cohrs** Engineering, Logistics Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg Small Cap Research **Ulrich Huwald** Health Care, Pharma Thilo Kleibauer Retail, Consumer Goods Eagert Kuls Engineering Andreas Pläsier Banks, Financial Services

INSTITUTIONAL EQUITY SALES

Holger Nass

Klaus Schilling

Tim Beckmann

Lyubka Bogdanova United Kingdom, Australia

Jens Buchmüller

Scandinavia, Austria Paul Dontenwill

Matthias Fritsch

SALES TRADING

United Kingdom

Oliver Merckel

Elyaz Dust

Sales Trading

Sales Trading

Carsten Klude

Macro Research

Bloomberg

FactSet

Warburg Research

Andrea Schaper

Sales Assistance

Head of Sales Trading

Michael Ilgenstein

MACRO RESEARCH

For access please contact:

Our research can be found under:

United Kinadom

Head of Equity Sales, USA

Dep. Head of Equity Sales, GER

USA, Poland, The Netherlands

mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-290 lboventer@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-255 uhuwald@warburg-research.com +49 40 309537-257 tkleibauer@warburg-research.com +49 40 309537-256 ekuls@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com

+49 40 3282-2669

+49 40 3282-2664

+49 40 3282-2665

+49 69 5050-7411

+49 69 5050-7415 jbuchmueller@mmwarburg.com

+49 40 3282-2666

+49 40 3282-2696

+49 40 3282-2634

hnass@mmwarburg.com

kschilling@mmwarburg.com

tbeckmann@mmwarburg.com

lboqdanova@mmwarburq.com

pdontenwill@mmwarburg.com

mfritsch@mmwarburg.com

omerckel@mmwarburg.com +49 40 3282-2702

milgenstein@mmwarburg.com

research.mmwarburg.com/en/index.html

edust@mmwarburg.com

+49 40 3282-2700

+49 40 3282-2572

MMWA GO

www.factset.com

+49 40 3282-2632

aschaper@mmwarburg.com

cklude@mmwarburg.com

+49 40 3282-2673

+49 40 309537-280

rrapelius@mmwarburg.com

Jochen Reichert Telco, Internet, Media J. Moritz Rieser Real Estate Arash Roshan Zamir Cap. Goods, Renewables Malte Schaumann Technology **Patrick Schmidt** Leisure. Internet **Oliver Schwarz** Chemicals, Agriculture Marc-René Tonn Automobiles, Car Suppliers Alexander Wahl Car Suppliers, Construction Andreas Wolf Software, IT

Michael Kriszun

United Kingdom

Germany

Marc Niemann

Sanjay Oberoi

Simon Pallhuber

Switzerland, France

Angelika Flegler

Roadshow/Marketing

Roadshow/Marketing

Bastian Quast

Sales Trading

Sales Trading

Jan Walter

Sales Trading

Investment Strategy

Thomson Reuters

Kerstin Muthig

Sales Assistance

Capital IQ

Dr. Christian Jasperneite

Jörg Treptow

Juliane Willenbruch

United Kingdom

+49 40 309537-130 jreichert@warburg-research.com +49 40 309537-260 mrieser@warburg-research.com +49 40 309537-155 aroshanzamir@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-125 pschmidt@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-230 awahl@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

+49 40 3282-2695 mkriszun@mmwarburg.com +49 40 3282-2660 mniemann@mmwarburg.com +49 69 5050-7410 soberoi@mmwarburg.com +49 69 5050-7414 spallhuber@mmwarburg.com

+49 69 5050-7417 aflegler@mmwarburg.com +49 40 3282-2694 jwillenbruch@mmwarburg.com

> +49 40 3282-2701 bquast@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com +49 40 3282-2662 jwalter@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

www.thomsonreuters.com www.capitaliq.com

+49 40 3282-2703 kmuthig@mmwarburg.com